{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:47:14Z","timestamp":1774280834083,"version":"3.50.1"},"reference-count":116,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.atherosclerosis.2010.03.011","type":"journal-article","created":{"date-parts":[[2010,3,17]],"date-time":"2010-03-17T09:14:08Z","timestamp":1268817248000},"page":"357-366","source":"Crossref","is-referenced-by-count":26,"title":["Phospholipase A2s: Developing drug targets for atherosclerosis"],"prefix":"10.1016","volume":"212","author":[{"given":"Keith","family":"Suckling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib1","first-page":"945","article-title":"The development of novel anti-hyperlipidemic drugs: a tough business gets tougher","volume":"9","author":"Krause","year":"2008","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17460440802623849","article-title":"What is the future for drug development in atherosclerosis and dyslipidaemia?","volume":"4","author":"Suckling","year":"2009","journal-title":"Exp Opin Drug Discov"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/MOL.0b013e32832dd4c7","article-title":"Phospholipase A2 inhibitors","volume":"20","author":"Garcia-Garcia","year":"2009","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10557-008-6148-1","article-title":"Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease","volume":"23","author":"Rosenson","year":"2009","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib5","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1517\/13543780903184583","article-title":"Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic","volume":"18","author":"Suckling","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib6","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1161\/ATVBAHA.108.173344","article-title":"Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression","volume":"28","author":"Devlin","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib7","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.bbalip.2006.07.011","article-title":"The phospholipase A(2) superfamily and its group numbering system","volume":"1761","author":"Schaloske","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib8","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.2174\/092986705774462860","article-title":"Inhibitors of secretory phospholipase A2 group IIA","volume":"12","author":"Reid","year":"2005","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib9","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0021-9150(00)80754-6","article-title":"Anti-atherosclerotic effect of SB-244323, a lipoprotein-associated phospholipase A2 inhibitor in WHHL rabbits","volume":"151","author":"Benson","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib10","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0960-894X(03)00058-1","article-title":"The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2","volume":"13","author":"Blackie","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib11","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1016\/S0021-9258(18)61336-5","article-title":"Human plasma platelet-activating factor acetylhydrolase. Purification and properties","volume":"262","author":"Stafforini","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/374549a0","article-title":"Anti-inflammatory properties of a platelet-activating factor acetylhydrolase","volume":"374","author":"Tjoelker","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib13","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1161\/01.ATV.16.4.591","article-title":"Sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins","volume":"16","author":"Tew","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib14","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev.biochem.76.062405.154007","article-title":"Biochemistry and physiology of mammalian secreted phospholipases A2","author":"Lambeau","year":"2008","journal-title":"Ann Rev Biochem"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10557-008-6134-7","article-title":"Biology of secretory phospholipase A2","volume":"23","author":"Boyanovsky","year":"2009","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib16","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s11883-008-0039-6","article-title":"Role of secretory phospholipases in atherogenesis","volume":"10","author":"J\u00f6nsson-Rylander","year":"2008","journal-title":"Curr Atherosclerosis Rep"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib17","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.bbalip.2006.07.003","article-title":"Activation of human inflammatory cells by secreted phospholipases A2","volume":"1761","author":"Triggiani","year":"2006","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11886-009-0064-2","article-title":"Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes","volume":"11","author":"Rosenson","year":"2009","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib19","first-page":"20","article-title":"Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function","author":"Karabina","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib20","first-page":"38","article-title":"Differential hydrolysis of molecular species of lipoprotein phosphatidylcholine by groups IIA, V and X secretory phospholipases A2","volume":"1736","author":"Pruzanski","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10557-008-6133-8","article-title":"Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2)","volume":"23","author":"Stafforini","year":"2009","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib22","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1161\/01.ATV.0000228821.79588.ef","article-title":"Human platelets secrete the plasma type of platelet-activating factor acetylhydrolase primarily associated with microparticles","volume":"26","author":"Mitsios","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib23","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1021\/bi002600g","article-title":"Platelet-activating factor acetylhydrolases: broad substrate specificity and lipoprotein binding does not modulate the catalytic properties of the plasma enzyme","volume":"40","author":"Min","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib24","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1074\/jbc.M709970200","article-title":"Electrospray ionization mass spectrometry identifies substrates and products of lipoprotein-associated phospholipase A2 in oxidized human low density lipoprotein","volume":"283","author":"Davis","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MOL.0b013e3283307c16","article-title":"Lipoprotein-associated phospholipase A(2) and atherosclerosis","volume":"20","author":"Wilensky","year":"2009","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib26","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1126\/science.1061781","article-title":"Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A","volume":"293","author":"Kabarowski","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib27","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1161\/01.ATV.0000246774.02426.71","article-title":"Loss of the lysophosphatidylcholine effector, G2A, ameliorates aortic atherosclerosis in low-density lipoprotein receptor knockout mice","volume":"26","author":"Parks","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib28","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1161\/ATVBAHA.109.191585","article-title":"Lysophosphatidylcholine activates a novel PKD2-mediated signaling pathway that controls monocyte migration","volume":"29","author":"Tan","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11010-006-9280-x","article-title":"Lysophosphatidylcholine induces inflammatory activation of human coronary artery smooth muscle cells","volume":"295","author":"Aiyar","year":"2007","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib30","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1074\/jbc.M706586200","article-title":"Migration to apoptotic \u201cfind-me\u201d signals is mediated via the phagocyte receptor G2A","volume":"283","author":"Peter","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib31","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.4049\/jimmunol.178.10.6540","article-title":"Lysophospholipids of different classes mobilize neutrophil secretory vesicles and induce redundant signaling through G2A","volume":"178","author":"Frasch","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib32","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1161\/01.ATV.0000040598.18570.54","article-title":"Expression of G2A, a receptor for lysophosphatidylcholine, by macrophages in murine, rabbit, and human atherosclerotic plaques","volume":"22","author":"Rikitake","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib33","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1161\/CIRCULATIONAHA.106.671420","article-title":"Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans","volume":"115","author":"Lavi","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib34","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/STROKEAHA.107.503193","article-title":"Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques","volume":"39","author":"Mannheim","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.cellsig.2006.07.007","article-title":"PKC\u03b1 regulates phosphorylation and enzymatic activity of cPLA2 in vitro and in activated human monocytes","volume":"19","author":"Li","year":"2007","journal-title":"Cell Signal"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbalip.2005.05.008","article-title":"Activation of phospholipase A2 and MAP kinases by oxidized low-density lipoproteins in immortalized GP8.39 endothelial cells","volume":"1735","author":"Lupo","year":"2005","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib37","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1074\/jbc.M409739200","article-title":"STAT-3-dependent cytosolic phospholipase A2 expression is required for thrombin-induced vascular smooth muscle cell motility","volume":"280","author":"Dronadula","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib38","first-page":"294","article-title":"Activation of cytosolic phospholipase A2 and fatty acid transacylase is essential but not sufficient for thrombin-induced smooth muscle cell proliferation","author":"Gluck","year":"2008","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib39","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1517\/17460441.1.6.507","article-title":"The ideal model in atherosclerosis and dyslipidaemia\u2014does it exist?","volume":"1","author":"Suckling","year":"2007","journal-title":"Exp Opin Drug Discov"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib40","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/ATVBAHA.107.142570","article-title":"Mouse Models for Atherosclerosis and Pharmaceutical Modifiers","volume":"27","author":"Zadelaar","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib41","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1161\/01.ATV.17.10.2257","article-title":"Expression of Phospholipase A2 Isoforms in Human Normal and Atherosclerotic Arterial Wall","volume":"17","author":"Elinder","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib42","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0021-9150(95)05604-1","article-title":"Secretory group II phospholipase A2 in human atherosclerotic plaques","volume":"118","author":"Menschikowski","year":"1995","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib43","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.bbalip.2006.06.008","article-title":"Distinctiveness of secretory phospholipase A(2) group IIA and V suggesting unique roles in atherosclerosis","volume":"1761","author":"Rosengren","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib44","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/01.ATV.0000221231.56617.67","article-title":"Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a Western diet","volume":"26","author":"Rosengren","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.atherosclerosis.2006.08.062","article-title":"Expression of secretory phospholipase A2s in human atherosclerosis development","volume":"196","author":"Kimura-Matsumoto","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib46","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1161\/01.ATV.19.12.2909","article-title":"Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions","volume":"19","author":"Hakkinen","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib47","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1161\/01.ATV.0000244681.72738.bc","article-title":"Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis","volume":"26","author":"Kolodgie","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib48","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1042\/0264-6021:3570457","article-title":"Platelet-activating factor acetylhydrolase and transacetylase activities in human plasma low-density lipoprotein","volume":"357","author":"Tsoukatos","year":"2001","journal-title":"Biochem J"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib49","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1194\/jlr.M800188-JLR200","article-title":"Platelet-activating factor acetylhydrolase and transacetylase activities in human aorta and mammary artery","volume":"49","author":"Tsoukatos","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib50","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1194\/jlr.M800342-JLR200","article-title":"Relationship of lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid atherosclerosis","volume":"50","author":"Vickers","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib51","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.pharmthera.2006.02.003","article-title":"Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease","volume":"111","author":"Chapman","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib52","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/sj.ijo.0803315","article-title":"Visceral adipose tissue accumulation, secretory phospholipase A2-IIA and atherogenecity of LDL","volume":"30","author":"Paradis","year":"2006","journal-title":"Int J Obes"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2796.2008.01932.x","article-title":"Increased lipolysis by secretory phospholipase A2 group V of lipoproteins in diabetic dyslipidaemia","volume":"264","author":"Pettersson","year":"2008","journal-title":"J Intern Med"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib54","doi-asserted-by":"crossref","first-page":"17099","DOI":"10.1074\/jbc.M802394200","article-title":"Identification of a domain that mediates association of platelet-activating factor acetylhydrolase with high density lipoprotein","volume":"283","author":"Gardner","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib55","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/01.ATV.0000160551.21962.a7","article-title":"Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target","volume":"25","author":"Zalewski","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib56","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1161\/01.ATV.0000280571.28102.d4","article-title":"New Insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease","volume":"27","author":"Tsimikas","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib57","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1007\/s00125-005-1899-8","article-title":"The inflammatory properties of electronegative low-density lipoprotein from type 1 diabetic patients are related to increased platelet-activating factor acetylhydrolase activity","volume":"48","author":"Sanchez-Quesada","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib58","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0022-2275(20)30167-X","article-title":"Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia","volume":"43","author":"Tsimihodimos","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib59","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1194\/jlr.M300129-JLR200","article-title":"The PON1 M55L gene polymorphism is associated with reduced HDL-associated PAF-AH activity","volume":"44","author":"Kakafika","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib60","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1161\/ATVBAHA.107.147280","article-title":"Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2","volume":"27","author":"Saougos","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib61","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1194\/jlr.M200452-JLR200","article-title":"Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins","volume":"44","author":"Tsimihodimos","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib62","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10557-008-6135-6","article-title":"Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence","volume":"23","author":"Koenig","year":"2009","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib63","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1161\/01.CIR.100.12.1280","article-title":"Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease","volume":"100","author":"Kugiyama","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib64","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.ATV.0000157933.19424.b7","article-title":"Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study","volume":"25","author":"Boekholdt","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib65","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2005.06.056","article-title":"Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes","volume":"46","author":"Mallat","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib66","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1161\/ATVBAHA.107.139352","article-title":"Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study","volume":"27","author":"Mallat","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib67","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/hmg\/ddi453","article-title":"Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study","volume":"15","author":"Wootton","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib68","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.clinbiochem.2008.09.101","article-title":"Circulating secretory type IIA phospholipase A2, lipoprotein (a) and soluble cellular adhesion molecule levels in patients with angina pectoris","volume":"41","author":"Ao","year":"2008","journal-title":"Clin Biochem"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib69","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJM200010193431603","article-title":"Lipoprotein-associated phospholipase A(2) as an independent predictor of coronary heart disease","volume":"343","author":"Packard","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib70","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/82.2.159","article-title":"Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review","volume":"82","author":"Garza","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib71","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.hjr.0000239464.18509.f1","article-title":"Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases","volume":"14","author":"Ballantyne","year":"2007","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib72","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1373\/clinchem.2008.107359","article-title":"Association of lipoprotein-associated phospholipase A2 mass and activity with coronary and aortic atherosclerosis: findings from the Dallas Heart Study","volume":"54","author":"Brilakis","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib73","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/HCO.0b013e32832bcb22","article-title":"Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target","volume":"24","author":"Packard","year":"2009","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib74","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1161\/ATVBAHA.107.151670","article-title":"Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease","volume":"27","author":"Sabatine","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib75","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/STROKEAHA.107.513259","article-title":"Lipoprotein-associated phospholipase A2 and High-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the atherosclerosis risk in communities (ARIC) study","volume":"40","author":"Nambi","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib76","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/hmg\/ddm094","article-title":"Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study","volume":"16","author":"Wootton","year":"2007","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib77","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00439-008-0587-4","article-title":"Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study","volume":"125","author":"Hou","year":"2009","journal-title":"Hum Genet"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib78","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0021-9150(03)00086-8","article-title":"Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe","volume":"168","author":"Abuzeid","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib79","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/hmg\/ddh145","article-title":"Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease","volume":"13","author":"Ninio","year":"2004","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib80","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.atherosclerosis.2005.12.009","article-title":"Lp-PLA2 activity and PLA2G7 A379V genotype in patients with diabetes mellitus","volume":"189","author":"Wootton","year":"2006","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib81","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1194\/jlr.M400253-JLR200","article-title":"Macrophage-specific overexpression of group IIa sPLA(2) increases atherosclerosis and enhances collagen deposition","volume":"46","author":"Ghesquiere","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib82","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1161\/01.ATV.0000257133.60884.44","article-title":"Group V secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice","volume":"27","author":"Bostrom","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib83","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/ATVBAHA.108.183038","article-title":"The capacity of group V sPLA2 to increase atherogenicity of ApoE\u2212\/\u2212 and LDLR\u2212\/\u2212 mouse LDL in vitro predicts its atherogenic role in vivo","volume":"29","author":"Boyanovsky","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib84","doi-asserted-by":"crossref","first-page":"33483","DOI":"10.1074\/jbc.M804628200","article-title":"Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis","volume":"283","author":"Sato","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib85","first-page":"S1096","article-title":"Abstract 5459: unexpected acceleration of atherosclerosis in Ldlr-null mice reconstituted with Group X secretory phospholipase A2-deficient bone marrow","volume":"120","author":"it-Oufella","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib86","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1161\/01.CIR.103.20.2495","article-title":"Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice","volume":"103","author":"Quarck","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib87","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1161\/01.ATV.0000067701.09398.18","article-title":"Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress","volume":"23","author":"Noto","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib88","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.atherosclerosis.2006.05.001","article-title":"Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses","volume":"191","author":"Shi","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib89","unstructured":"Ramarao M. Characterization of cPLA cPLA2 alpha Inhibitors by Microcalorimetry. http:\/\/www.microcal.com\/documents\/cPLA-alpha-inhibitors-microcalorimetry.pdf [accessed 04.11.09]."},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib90","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/cvr\/cvn234","article-title":"Secreted phospholipase A2 type IIA as a mediator connecting innate and adaptive immunity: new role in atherosclerosis","volume":"81","author":"Ibeas","year":"2009","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib91","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2006.09.024","article-title":"Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation","volume":"194","author":"Luchtefeld","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib92","doi-asserted-by":"crossref","first-page":"8374","DOI":"10.1128\/MCB.00623-07","article-title":"Inhibition of interleukin-1\u03b2-induced group IIA secretory phospholipase A2 expression by peroxisome proliferator-activated receptors (PPARs) in rat vascular smooth muscle cells: cooperation between PPAR\u03b2 and the proto-oncogene BCL-6","volume":"27","author":"Ravaux","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib93","doi-asserted-by":"crossref","first-page":"32746","DOI":"10.1074\/jbc.M502067200","article-title":"Group V secretory phospholipase A2-modified low density lipoprotein promotes foam cell formation by a SR-A- and CD36-independent process that involves cellular proteoglycans","volume":"280","author":"Boyanovsky","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib94","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1194\/jlr.M800450-JLR200","article-title":"Syndecan-4 mediates macrophage uptake of group V secretory phospholipase A2-modified LDL","volume":"50","author":"Boyanovsky","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib95","first-page":"S469","article-title":"Abstract 1277: group X secretory phospholipase A2 negatively regulates activation of liver X receptors","volume":"120","author":"Shridas","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib96","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1042\/0264-6021:3380479","article-title":"Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor","volume":"338","author":"Macphee","year":"1999","journal-title":"Biochem J"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib97","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1194\/jlr.M500555-JLR200","article-title":"Specific monocyte adhesion to endothelial cells induced by oxidized phospholipids involves activation of cPLA2 and lipoxygenase","volume":"47","author":"Huber","year":"2006","journal-title":"J Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib98","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1042\/bj20040069","article-title":"Lysophosphatidylcholine and 7-oxocholesterol modulate Ca2+ signals and inhibit the phosphorylation of endothelial NO synthase and cytosolic phospholipase A2","volume":"380","author":"Millanvoye-Van Brussel","year":"2004","journal-title":"Biochem J"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib99","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00041433-200406000-00015","article-title":"Platelet-activating factor acetylhydrolase: is it good or bad for you?","volume":"15","author":"Chen","year":"2004","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib100","first-page":"417","article-title":"A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A 2, in the treatment of rheumatoid arthritis","volume":"32","author":"Bradley","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib101","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1097\/01.CCM.0000171540.54520.69","article-title":"LY315920NA\/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis","volume":"33","author":"Zeiher","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib102","first-page":"400","article-title":"Phospholipase A2: quo vadis?","volume":"32","author":"Pruzanski","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib103","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1016\/S0960-894X(02)00473-0","article-title":"The discovery of SB-435495: a potent, orally active inhibitor of lipoprotein-associated phospholipase A2 for evaluation in man","volume":"12","author":"Blackie","year":"2002","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib104","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0022-3565(24)38064-4","article-title":"Pharmacology of LY315920\/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetate, a potent and selective secretory phospholipase A2 inhibitor: a new class of anti-inflammatory drugs, SPI","volume":"288","author":"Snyder","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/FJC.0b013e318195bfbc","article-title":"Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE \u2212\/\u2212 mice","volume":"53","author":"Fraser","year":"2009","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib106","first-page":"9","article-title":"A-002 (Varespladib), a phospholipase A2 inhibitor, reduces atherosclerosis in guinea pigs","author":"Leite","year":"2009","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib107","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1161\/CIRCULATIONAHA.107.743997","article-title":"Reduction in myocardial ischemia\/reperfusion injury in group X secretory phospholipase A2-deficient mice","volume":"117","author":"Fujioka","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib108","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/nm.1870","article-title":"Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development","volume":"14","author":"Wilensky","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib109","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0140-6736(09)60403-7","article-title":"Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial","volume":"373","author":"Rosenson","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib110","unstructured":"FRANCIS-ACS trial: a study of the safety and efficacy of A 002 in subjects with acute coronary syndromes. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00743925?term=varespladib&rank=1 [accessed 09.11.09]."},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib111","unstructured":"Anthera's varespladib meets primary endpoint in p2 Francis trial for the treatment of acute coronary syndrome. http:\/\/www.anthera.com\/may062009.html [accessed 09.11.09]."},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib112","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/MOL.0b013e3282f19608","article-title":"Atherosclerosis imaging as a benchmark in the development of novel cardiovasular drugs","volume":"18","author":"Duivenvoorden","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib113","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1161\/CIRCULATIONAHA.108.771899","article-title":"Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque","volume":"118","author":"Serruys","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib114","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.jacc.2007.11.079","article-title":"The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study","volume":"51","author":"Mohler","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib115","unstructured":"The stabilization of atherosclerotic plaque by initiation of darapladib therapy trial (STABILITY). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00799903. ClinicalTrials.gov. [accessed 19.01.10]."},{"key":"10.1016\/j.atherosclerosis.2010.03.011_bib116","unstructured":"The stabilization of plaques using darapladib-thrombolysis in myocardial infarction 52 trial (SOLID-TIMI 52). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01000727. ClinicalTrials.gov. [accessed 19.01.10]."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915010002273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915010002273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T14:22:20Z","timestamp":1739974940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915010002273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":116,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0021915010002273"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2010.03.011","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}